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Abstract
Background: Statins are considered as standard drugs to control cholesterol levels, but their use is also associated
with renal hypertrophy, hemorrhagic stroke, hepatomegaly, and myopathy. Murraya koenigii is an herb that is used
in traditional cuisine and as a medicine in South Asia. Here we assessed the antidyslipidemic and antiatherosclerotic
effects of this spice in repeated heated mix vegetable oils (RHMVO)-induced atherosclerotic models.
Methods: Aqueous extract of M. koenigii leaves (Mk LE) was prepared and its phytoconstituents were determined.
Rabbits were divided into 5 groups (n = 10). Except for the control group, all the other four groups were treated
with RHMVO for 16 weeks (dose = 2 ml/kg/day) to induce dyslipidemia and atherosclerosis. These groups were
further treated for 10 weeks either with 300 and 500 mg/kg/day Mk LE, lovastatin, RHMVO, or left untreated. Body
and organ weights were measured along with oxidative stress and tissue damage parameters. Lipid profile and
hepatic function markers were studied. Atheroma measurement and histopathological examination were also
performed in control and treated groups.
Results: Mk LE significantly (p < 0.05) attenuated RHMVO-induced dyslipidemia and atheroma formation.
Furthermore, fat accumulation and lipid peroxidation in hepatic tissues were reduced by Mk LE in a dosedependent manner. Our results indicated that the antidyslipidemic effects of Mk LE in 500 mg/kg/day dose were
comparable to lovastatin. Additionally, oxidative stress markers were reduced much more significantly in Mk LE-500
than in the statin group (p < 0.05).
Conclusions: This study recommends Mk LE as a potent antioxidant and lipid-lowering natural medicine that can
attenuate the RHMVO-induced atherosclerotic in optimal doses and duration. Therefore, Mk LE can be accessible,
cheap, and free of adverse effects alternate to statins.
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Background
In modern society, altered food consumption pattern
increases incidences of metabolic syndrome, including
obesity, hypertension, diabetes, atherosclerosis, stroke,
and cancer [1–4]. Particularly dyslipidemia is considered as the basic cause of health concerns, related to
metabolic syndrome [2]. As per National Cholesterol
Education Program Adult Treatment Panel III
(NCEP-ATP) guidelines, dyslipidemia is characterized
as triglycerides (TG) > 150 mg/dl, total serum cholesterol (TC) > 200 mg/dl, low-density lipoproteins (LDL)
> 100 mg/dl and high-density lipoproteins (HDL) less
than 40 mg/dl. Dyslipidemia is the most important
risk factors of cardiovascular diseases (CVDs) and
atherosclerosis [5, 6].
Cholesterol is transported to the liver for metabolism,
by HDL, whereas endothelial injuries and formation of
atheroma are triggered by oxidized LDL molecule.
Therefore, reduction of LDL and TC, along with HDL
level enhancement is targeted to prevent atherosclerosis
[7]. So far, statins have been utilized for inhibiting cholesterol biosynthesis, by restraining 3-hydroxy-3methylglutary-coenzyme A (HMG-CoA). In addition,
statins induce the cellular level of LDL receptors activity
that in turn facilitates the metabolism of LDL and verylow-density lipoproteins (VLDL) [8, 9]. However, despite
this benefit, long-term use, and/or over-dosage of statins
results in serious adverse effects, such as renal hypertrophy, hemorrhagic stroke, hepatomegaly, and myopathy [10–12]. These facts are driving the researchers to
explore the solution from nature to regulate blood flow
and control the blood cholesterol levels, with the least
adverse effects.
Physico-chemical characteristics of the cooking oils
change when they are heated beyond a certain limit as
several chemical reactions take place in the presence of
moisture and air. Oils degenerate and produce volatile
substances, unwanted monomers, polymers, isomers,
and free radicals [13]. In cooking oil fatty acids (FAs)
naturally exist in the cis-isomer form, but during thermal oxidation they convert into trans-isomers, possessing physical properties similar to saturated FAs [14].
Several animal studies demonstrate that consumption of
thermally oxidized vegetable oils increased the risk of
CVDs, like hypertension with reduced vasorelaxation responses [15], endothelial malfunction [16], lipid peroxidation [17], atherosclerosis [18], and oxidative stress
[19]. However, regardless of all these studies, the practice of reusing and overheating the cooking oils while
processing the food seems to continue.
M. koenigii (curry leaves) are commonly used spices in
Pakistani cuisine. With the vast range of biological activities such as antidyslipidemic [20–22], platelet aggregation inhibiting [23], antioxidant [24], and hypoglycemic
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activities [25], it gained the attention of researchers
worldwide. Several animal studies have reported this
spice as a potent antidyslipidemic agent and the response was achieved in 4–8 weeks, in a dose-dependent
manner [20, 21]. A recent human study, conducted on
45–65 years women of postmenopausal phase with
hyperlipidemia, also reported that M. koenigii leaves intake for 45 consecutive days can significantly reduce the
blood lipid levels [22]. A study also reported that Mk LE
inhibits platelet aggregation, resulting in improved blood
flow [23]. It also acts as an antioxidant, further suppressing the vascular inflammatory response through reduced
reactive oxygen species (ROS) production [26].
Presently, several animal models have been used to
study hyperlipidemia induced atherosclerosis, like
mice [27], zebrafish [28], rats [29, 30], and pigs [31].
To study the effect of curry leaves on thermally oxidized oil-induced hypercholesterolemia and atherosclerosis selection of experimental animal models is
very critical to conduct basic research and develop a
study tool. In this respect, to study human hyperlipidemia the rabbit has become the most appropriate animal model because of rabbits’ unique features of lipid
metabolism similar to humans [32, 33]. Several studies also used rabbit model for cardiac diseases [34].
Rabbit as an experimental animal is also considered
appropriate for the Rabbit as an experimental animal
model is also used to evaluate the medicinal effects of
several herbal medicines, like the hypolipidemic effect
of Ficus bengalensis [35], the hypoglycemic effect of
Achyranthes aspera [36] antihyperglycemic effects of
Alpinia galanga rhizome and its extracts [37], and
hypoglycemic effects of M. koenigii [25].
In Pakistan, commercially available oils are mostly a
blend of two or more edible oils, and the most common
available blend of an equal ratio of olive, canola, and
sunflower oils was focused in this study, to have the
model that mimics the human situation. Vegetable oils
are repeatedly heated when used for food processing
(frying) at household and commercial levels. We used
repeatedly heated mixed vegetable oils (RHMVO) to induce hyperlipidemia and atherosclerosis. We designed
this study to investigate the medicinal effects of curry
leaves in different doses, in RHMVO-induced atherosclerotic models.

Methods
Collection and identification of oils and plant material

Fresh curry leaves, standard food-grade canola, sunflower, and olive oils were purchased from Karachi local
market. The specimen of plant material and oils were
verified by the Department of Pharmacognosy, University of Karachi.
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Oil sample preparation

Olive, canola, and sunflower oils were mixed in equal ratio and heated beyond the smoke point of the oil mixture at 220 °C for 45 min each day for a total of ten days
[38–40]. The smoke point for olive oil, canola oil, sunflower oil is 180 °C, 200 °C, and 225 °C, respectively [41,
42]. Every day before heating, the oil level was adjusted
in the pan with the same oils blend (0.007 ± 0.003 l per
day) to meet the initial level. This replenishment method
was adopted to replicate the same practices used in fried
and fast food outlets [38]. At the end of the 10th day,
viscous dark brown oil was obtained. To prevent photodegradation it was stored in amber color bottles and labeled as RHMVO [43].
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first 16 weeks, except for the control, all other groups
were treated with 2 ml/kg/day of RHMVO to induce
hypercholesterolemia [43]. The induction period was
followed by the treatment period of 10 weeks. In the
treatment period animals were treated as follows
 Control group: Untreated
 RHMVO group: Rabbits continued to have 2 ml/kg/

day RHMVO
 Mk LE-300 group: Rabbits were given Mk LE 300

mg/kg/day
 Mk LE-500 group: Rabbits were given Mk LE 500

mg/kg/day
 Statin group: Rabbits were given lovastatin 0.5 mg/

kg/day
Preparation of Murraya koenigii leaves extract (Mk LE)

Curry leaves were cleaned by thorough washing to remove any contamination with double-distilled water.
Washed curry leaves were dried in shade at room
temperature and grounded to powder with the help of a
mechanical grinder and then preserved at room
temperature in an airtight container. Three hundred
grams powdered leaves were subjected to cold extraction
by stirring them in 4-l double-distilled water for 24 h.
The resultant suspension was centrifuged at 10,000×g
for 10 min and filtered through Whatman No. I filter
paper, followed by a 0.45 μm membrane filter (Sartorius
minisart, Hannover, Germany). Finally, the filtrate was
dried using a rotary evaporator and resulted in a 13.6%
yield. The dried extract was dissolved in distilled water
to achieve 100 mg/ml stock. Crude aqueous extract of
curry leaves (Mk LE) was then kept at 4 °C storage
temperature for subsequent use for planned
experiments.
Experimental animals

Healthy adult male rabbits of local strain weighing between 1450 ± 10 g were purchased from the department
of pharmacology, University of Karachi, Pakistan. Male
rabbits were selected to avoid the sex difference due to
female sex hormonal effects on CVDs [44, 45]. Secondly,
the prevalence of plasma lipid abnormalities in Pakistan,
are higher in males than females [46, 47]. Rabbits were
kept individually in wire-topped steel cages with a
wooden bottom, under controlled humidity (50–60%),
and temperature (23 °C ± °C) with 12/12 h light/dark
photo-cycle. Animals were acclimatized for 7 days before
starting the experiment. Animals were handled according to the institutional animal’s ethical committee
guidelines.
Experimental design

The total experimental period was of 26 weeks and all
animals were divided into five groups (n = 10). In the

From the statin group, we selected lovastatin, to avoid
the additional side effects (nasopharyngitis, diarrhea, and
urinary tract infection) which are associated with other
statins [48]. Oil and Mk LE were administered daily in
the morning and lovastatin in the evening through the
oral route, with the help of oral syringes [49]. Lovastatin,
a short-acting statin, is prescribed to be taken in the
evening to achieve better results as cholesterol production through livers enzymes is higher in these hours [50,
51]. For the rest of the day animals of all the groups
were fed ad libitum on a regular normal diet (fresh hay
and water). Morbidity and mortality were monitored
through the study period. Animal’s body weight was recorded at baseline, week 1, 16, 20, 23, and 26. After the
induction period (at 16 weeks) and treatment period (at
26 weeks), 3 rabbits from each group were euthanized
through the intravenous administration of sodium
pentobarbital 100 mg/kg followed by decapitation [52].
Furthermore, animals were necropsied for histopathological examination of internal organs and to retrieve
liver, heart, spleen and kidney for organs weight
evaluation.
Blood sample collection for lipid profile and liver function
markers

Blood samples were collected from the ear vein of animals at week 1, 16, 20, 23, and 26. For hematological
parameters, 2 ml blood was collected in EDTA and 5
ml in gel vacutainers to perform the biochemical assays. Blood was centrifuged to collect plasma and
serum and stored at − 20 °C until used further to
analyze the plasma lipid profile (TG, TC, HDL, LDL,
VLDL) and liver function markers, such as total protein, albumin, serum glutamic-pyruvic transaminase
(SGPT), serum glutamic-oxaloacetic transaminase
(SGOT) and alkaline phosphatase (ALP) using commercially available kits (RANDOX Laboratories Ltd)
followed by manufacturer’s instructions.
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Oxidative stress and tissue damage parameters

Lipid peroxidation was measured by determining plasma
malondialdehyde (MDA), following Kikugawa et al
method [53]. The plasma C-reactive protein (CRP) was
measured by using an ELISA kit (Abnova, Taipei,
Taiwan), as per the manufacturer’s instruction. A commercially available kit was used to analyses lactate dehydrogenase (LDH) (BioVision, USA). We followed
Hamsi et al. method to prepare the samples and standards [54]. Sheu et al. method was adopted to measures
the fasting plasma homocysteine concentrations [55].
Creatine phosphokinase (CPK) was measured by a commercially available kit from Beckman Coulter, Brea,
USA, following manufacturer instructions.
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mentioned in mg gallic acid equivalents (GAE) per each
gram of extract, where GA was considered as standard.
Total flavonoids are mentioned as mg catechin equivalents (CE) per each gram of extract, catechin was used
as standard. For the quantitative finding of the total alkaloid content in the Mk LE, we followed the method of
Sreevidya et al [60] and expressed as mg/g bismuth nitrate. Total tannin content was evaluated by following
the Polshettiwar et al method [61] and expressed as tannic acid equivalent per gram of Mk LE. Total chlorophyll content was evaluated by following the method
adopted in Kizhedath and Suneetha study [62] and
expressed as mg pigments/gm.
Statistical analysis

Atheroma measurement

After 26 weeks animals were sacrificed as per the guidelines and necropsied to dissect a 10 cm aortic arch from
the aortic valve and washed in normal saline followed by
further dissection to open the orifice of the carotid artery (5 cm long) with a longitudinal cut. After removal of
adhered tissue, propylene glycol (100%) was used to dehydrate the aorta, for 10 min followed by another 10 min
staining 0.7% Sudan IV (in propylene glycol) [56–58].
The tissue was re-hydrated by treating it with 85% propylene glycol for 5 min, washed with distilled water, and
photographed. Digital Image Analyzer was used to
analyze the red atheromatous plaques. We measured the
degree of lipid deposition by calculating the percent atherosclerosis index (AI) through the ratio between the
Sudan-positive area to the whole aortic wall area.
Microscopic examination

After weighing liver tissues, samples were treated with
alcohol to dehydrate. After cleaning with xylene, samples
were further embedded in paraffin at 56 °C. By using a
rotatory microtome, 5 μm sized sections were obtained,
mounted onto albumenized slides, and kept for drying
for 12 h. Dewaxing was done in xylene and hydration
was performed in ethanol and water. The sections were
first treated with Harris hematoxylin to stain, thereafter
differentiation by acid alcohol, and then staining in
methylene blue was performed. Furthermore, dehydration of sections in alcohol (95%) and staining in alcoholic eosin (10%), dehydration with absolute alcohol,
and cleaning with xylene were completed. The sections
were then mounted using Canada balsam. These prepared slides were finally viewed with the use of a light
microscope.

Data is represented in the form of mean ± standard deviation. We applied analysis of variance (ANOVA)
followed by post hoc Tukey’s honest significant difference (HSD) test to find out statistical significance at p <
0.05. Statistical product and service solutions software
was used.

Results
Biometric parameters

No death and unexpected signs and symptoms noticed
in experimental animals throughout the study period in
the treated animals and control. The body and organ
weights of animals in all the groups increased gradually
with age (Table 1 and Fig. 1). Bodyweight of all the animals treated with RHMVO was significantly higher than
control, after the induction period of 16 weeks. At 26
weeks animals in the RHMVO group exhibited significantly higher weight than the age-matched other groups.
However, statistically insignificant differences were
present in the bodyweight of Mk LE-300, Mk LE-500
and lovastatin groups at 20th week, but at the end of
26th week, this phenomenon became very considerable
and statistically significant body weight reduction was
observed in Mk LE treated groups in a dose-dependent
manner compared to RHMVO fed group (p < 0.05).
Moreover, weight reduction was also statistically significant in the lovastatin treated group (p < 0.05), but lesser
than the Mk LE-500 group. As shown in Table-1 organs
weight reduction of Mk LE treated groups in the treatment phase was dose-dependent and statistically highly
significant (p < 0.005) in 500 mg/kg/day doses. Organ
weight reduction in Mk LE-500 treated group was even
higher than the lovastatin treated group.
Serum biochemical analysis of lipid profile

Phytoconstituents determination of Mk LE

For the quantitative measurement of the total content of
flavonoids and phenols in the Mk LE, we followed the
methods of Sefi et al [59]. Total phenol content is

As shown in Table 2, animals in RHMVO exhibited
higher TGs, TC, LDL, VLDL, and lower HDL circulating
levels in comparison with control. After 26 weeks of
RHMVO feeding the TGs and TC values increased

Ambreen et al. BMC Complementary Medicine and Therapies

(2020) 20:222

Page 5 of 12

Table 1 Comparison of organs weight post-induction and after-treatment
Organs

Observation Time

Control (weight-g)

RHMVO (weight-g)

Mk LE-300 (weight-g)

Mk LE-500 (weight-g)

Lovastatin (weight-g)

Liver

Post induction (week16)

53.66 ± 1.35

86.25 ± 2.62

87.38 ± 1.88

85.26 ± 1.92

86.24 ± 2.22

After treatment (week26)

60.31 ± 4.33

104.95 ± 2.6 ##

83.76 ± 1.89

63.17 ± 2.56 **

75.51 ± 2.26*

Post induction (week16)

34.37 ± 1.47

56.89 ± 2.15

57.1 ± 2.25

55.75 ± 3.09

55.09 ± 3.46

After treatment (week26)

40.88 ± 3.42

74.96 ± 4.5 #

54.08 ± 2.26

42.48 ± 1.2**

51.27 ± 2.52

Spleen

Heart

Kidney

Post induction (week16)

18.08 ± 1.39

34.75 ± 0.9

34.92 ± 1.09

34.9 ± 1.14

34.95 ± 1.15

After treatment (week26)

18.54 ± 5.92

49.17 ± 4.84 #

32.83 ± 1.09

29.31 ± 1.14*

31.86 ± 1.12

Post induction (week16)

14.41 ± 0.9

27.74 ± 1.53

27.97 ± 1.63

27.77 ± 1.74

28.11 ± 1.94

After treatment (week26)

17.98 ± 2.43

37.16 ± 2.18 ##

25.99 ± 1.28

21.05 ± 1.38*

25.6 ± 0.55

*Significantly reduced from post-induction weight (p < 0.05)
**Significantly reduced from post-induction weight (p < 0.005)
# significantly increased from the post-induction weight (p < 0.05)
## Significantly increased from post-induction weight (p < 0.005)

about 4–5 folds in the RHMVO group. Whereas in Mk
LE treated groups all these parameters improved in a
dose-dependent manner and statistically significant
(p > 0.05) changes were observed in Mk LE-500 and lovastatin groups. Although, at weeks 20 and 23 there was
no such obvious difference between Mk LE-300, Mk LE500, and statin groups. But at the end of 26 weeks Mk
LE-500 group animals presented significantly (p > 0.005)
improved lipid profile than Mk LE-300 and comparable
to statin group. At the end of treatment HDL levels were

significantly higher in the Mk LE-500 group compared
to the control group.
Hepatic function and oxidative stress markers

The biochemical analysis of liver function markers has
shown that continuous feeding of RHMVO induced
hypercholesterolemia, which resulted in significantly
(p < 0.005) reduced total protein and albumin levels. The
blood levels of LDH, CPK, SGOT, SGPT, and ALP were
also increased significantly, suggestive of liver

Fig. 1 Graphical Presentation, Comparing the Weight Gain in Different Groups During the Study Period (at 95% CI): (Control = Blue line showing
the gradual increment in bodyweight with age, RHMVO fed group = Green line showing significant weight gain, Mk LE-300 group = Brown
line showing the weight reduction over week 16 to 26, lovastatin group = Red line showing significant weight reduction, Mk LE-500 group =
Purple line showing the significant weight reduction comparable with red line of lovastatin group
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Table 2 Comparison of lipid profile through the study period (baseline till week-26)
Observation Time

Control

RHMVO

Mk LE-300

Mk LE-500

Lovastatin

week 1-baseline (Before induction)

56.32 ± 3.51

55.43 ± 2.21

55.62 ± 3.28

57.08 ± 3.80

56.58 ± 3.18

week 16 (Post induction)

69.08 ± 2.92

272.18 ± 1.76**

279.61 ± 6.76**

281.4 ± 6.03**

276.01 ± 12.31**

week 20

73.17 ± 2.11

309.26 ± 1.83**

251.83 ± 6.16

256.01 ± 6.19

255.67 ± 12.05

week 23

74.75 ± 3.42

330.61 ± 1.55**

220.05 ± 6.28

218.76 ± 5.05

224.46 ± 12.92

week 26

75.93 ± 4.0

352.07 ± 6.74**

179.06 ± 6.09 #

166.51 ± 3.08 ##

195.2 ± 12.41#

week 1- baseline (Before induction)

141.02 ± 3.21

140.12 ± 3.25

141.21 ± 5.02

141.30 ± 3.55

141.25 ± 1.58

week 16 (Post induction)

148.54 ± 4.25

444.5 ± 8.23**

446.31 ± 8.59**

450.35 ± 8.91**

443.29 ± 11.61**

week 20

150.19 ± 5.23

503.45 ± 8.09**

394.07 ± 8.23

378.1 ± 8.09

388.08 ± 11.06

week 23

151.84 ± 3.02

562.4 ± 8.55**

350.75 ± 7.99

289.85 ± 8.23#

333.82 ± 11.31

week 26

154.4 ± 3.87

637.75 ± 9.99**

308.51 ± 8.32#

200.59 ± 8.59##

280.61 ± 11.38##

week 1- baseline (Before induction)

48.23 ± 3.29

47.22 ± 1.29

48.01 ± 3.31

47.59 ± 3.98

47.29 ± 3.19

week 16 (Post induction)

67.66 ± 3.31

367.61 ± 15.22**

366.21 ± 18.30**

363.57 ± 14.69**

361.63 ± 14.17**

week 20

68.87 ± 3.06

405.59 ± 18.23**

351.9 ± 15.09

326.36 ± 14.09

326.62 ± 14.29

week 23

69.72 ± 3.25

439.84 ± 10.59**

333.59 ± 11.66

271.24 ± 11.05

278.36 ± 10.09

week 26

73.92 ± 2.88

481.22 ± 75.05**

311.35 ± 18.36

213.59 ± 10.29##

240.65 ± 12.07#

week 1- baseline (Before induction)

11.08 ± 0.56

11.22 ± 0.77

11.21 ± 0.81

11.10 ± 0.67

11.02 ± 0.66

week 16 (Post induction)

14.88 ± 0.74

82.18 ± 3.97**

82.73 ± 4.49**

84.27 ± 4.29**

82.55 ± 3.89**

week 20

15.84 ± 0.70

90.43 ± 3.29**

77.52 ± 4.20

73.06 ± 5.20

72.38 ± 3.34

week 23

16.65 ± 0.62

98.68 ± 5.02**

70.31 ± 4.35

55.85 ± 4.35#

60.49 ± 3.09

week 26

16.52 ± 0.53

105.55 ± 3.07**

62.2 ± 2.21

30.64 ± 4.04##

48.51 ± 4.52#

week 1- baseline (Before induction)

53.23 ± 8.69

53.33 ± 7.05

53.53 ± 6.05

54.59 ± 6.29

53.09 ± 8.34

week 16 (Post induction)

69.64 ± 3.35

16.08 ± 1.67$$

15.78 ± 2.17$$

15.03 ± 2.22$$

15.03 ± 2.19$$

week 20

70.92 ± 6.09

13 ± 1.38$$

21.99 ± 2.01

32.18 ± 2.56^

24.28 ± 2.65

TRIG (mg/dl)

TC (mg/dl)

LDL (mg/dl)

VLDL (mg/dl)

HDL (mg/dl)

week 23

71.18 ± 2.95

9.32 ± 2.08$$

40.08 ± 3.55^

67.43 ± 4.05^^

34.63 ± 5.29^

week 26

73.92 ± 5.01

5.64 ± 2.59$$

58.06 ± 3.23^

81.68 ± 2.92^^ %

42.89 ± 4.84^

**highly significant difference (p < 0.005) (increased values) than week 1- baseline (Before induction) values
# significant difference (p < 0.05) (decreased values) than week 16- (post induction) values
## highly significant difference (p < 0.005) (decreased values) than week 16- (Post induction) values
$$ highly significant difference (p < 0.005) (decreased values) than week 1- baseline (Before induction) values
^ significant difference (p < 0.05) (increased values) than week 16- (post induction) values
^^ highly significant difference (p < 0.005) (increased values) than week 16- (post induction) values
% significant difference (p < 0.05) (increased values) than control group in corresponding weeks
TRIG Triglycerides, TC Total cholesterol, LDL Low-density lipoproteins, VLDL Very-low-density lipoproteins, HDL High-density lipoproteins

dysfunction with reduced protein synthesis and hepatic
injury. With the treatment of Mk LE, hepatic function
markers were restored in a dose-dependent manner, but
significantly in Mk LE-500 group (p < 0.005). In lovastatin (0.5 mg/kg/day) treated group few parameters improved significantly after 10 weeks of treatment (p <
0.05).
At the end of the induction period, oxidative stress
and inflammation were also significantly (p < 0.005) increased with RHMVO feeding, shown by elevated MDA

and CRP levels. Mk LE in higher doses of 500 mg/kg
was enough to restore the normal levels after 10 weeks
of treatment (p < 0.005). Lovastatin (0.5 mg/kg/day)
treated group exhibited a lesser impact on inflammatory
and oxidative stress markers over 10 weeks period
(Table 3).
Chemical analysis of the extract

Dry powder of curry leaves yielded 13.6% components by
weight (water-soluble). The quantitative characterization

(2020) 20:222
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Table 3 Comparison of oxidative stress and liver function markers at week-26
Variables

Control ##

RHMVO**

Mk LE-300

Mk LE-500

Lovastatin

CPK (U/L)

148.17 ± 2.29

1116.85 ± 9.27

981.81 ± 8.55**

562.84 ± 13.78 ** ##

947.84 ± 17.41** #

LDH (U/L)

212.44 ± 45.38

1214.21 ± 9.71

986.64 ± 4.86** #

508.13 ± 9.05 * ##

831.42 ± 12.85 ** #

Homocysteine (μMol/L)

4.62 ± 0.54

15.88 ± 1.08

10.57 ± 1.33* #

5.26 ± 1.04 ##

11.33 ± 0.91**

MDA (nMol/ml)

8 .00 ± 1.43

29.7 ± 1.32

20.68 ± 2.42** #

12.14 ± 1.69 * ##

19.77 ± 1.71 ** #

CRP (mg/dl)

0.04 ± 0.01

14.64 ± 2.16

11.93 ± 1.52** #

4.39 ± 1.57 * ##

9.81 ± 0.98**

SGPT (U/L)

92.9 ± 4.65

376.23 ± 8.33

305.5 ± 2.85**

208.93 ± 70.98 * ##

301.82 ± 10.57**

SGOT (U/L)

95.28 ± 5.11

404.28 ± 8.77

311.41 ± 3.91**

185.3 ± 35.78 * ##

315.42 ± 6.45**

ALP (U/L)

82.89 ± 4.8

635.25 ± 4.98

556.35 ± 3.07**

217.2 ± 9.26 * ##

355.59 ± 6.82** #

Total Protein (mg/dl)

7.42 ± 0.43

2.5 ± 0.24

3.51 ± 0.25*

5.45 ± 0.29 * #

2.11 ± 0.13**

Albumin (mg/dl)

3.42 ± 0.46

1.08 ± 0.04

2.06 ± 0.05#

3.09 ± 0.12##

1.56 ± 0.43*

*Significantly different from Control (p < 0.05). #significantly different from RHMVO (p < 0.05). **Significantly different from Control (p < 0.005). ##significantly
different from RHMVO (p < 0.005)

of the chemical in Mk LE showed the significant existence
of alkaloid, flavonoid, chlorophyll, polyphenol, and tannin
(Table 4).
Effect on atheromatous plaques area

As shown in Fig. 2, at the end of 26 weeks RHMVO
feeding resulted in extensive atheromatous plaques formation, covered about 80–85% of the aortic arch. This
atheromatous plaque was noticeably attenuated by Mk
LE in a dose-dependent manner at the end of the treatment phase. Atheromatous plaque reduced to 60 and
40% in 300 mg and 500 mg Mk LE doses respectively.
The atheroma area was reduced by lovastatin (0.5 mg/
kg/day) to 57% after 10 weeks of treatment.
Hepatic histological observations

Under the microscopic observations, widespread lipid
accumulation was observed in hepatocytes in the
RHMVO group (Fig. 3). The point of interest is the
remarkable dose-dependent attenuation of RHMVOinduced hepatic steatosis with Mk LE treatment. The effect of Mk LE-500 is greater than the lovastatin.

Discussion
Alternative medicines are getting an important place to
manage different health problems and rising as a wide
field of research. Management of hyperlipidemiainduced atherosclerosis also relies on alternative

medicine as an upcoming changed trend to protect and
treat. Using the animal model, we created a real-life scenario and induced hyperlipidemia and atheroma formation with RHMVO and considered herbal nutritional
sources to manage it.
The results of this study establish that Mk LE has the
potential to treat the RHMVO-induced hyperlipidemia
and atherosclerosis. The extract is found as a rich source
of polyphenols, alkaloids, chlorophyll, and flavonoids.
The quantitative analysis of curry leaves aqueous extract
reported that there are constituents with antioxidant
properties, the main reason for using curry leaves as alternative medicines and nutritional supplements in oxidative stress-induced disease studies [63–65]. Mk LE,
with its immense health benefits, has been reported as a
protective remedy against oxidative stress-induced diabetes [66]. The aqueous extract of curry leaves also has
prolific antioxidant activities against lead and cadmiuminduced oxidative stress in animal models [66, 67]. Several in vivo [68, 69] and in vitro [70, 71] studies reported
the free-radical scavenging ability and antioxidant potential of curry leaves extract concluding the immediate and
strong ameliorative actions for treating oxidative stress.
Considering the same facts, in this study we evaluated
the dose-dependent effect of curry leaves, to treat the
hyperlipidemia and oxidative stress induced by the high
dose of thermally oxidized cooking oils blend. The impact was also compared with standard i.e. lovastatin

Table 4 Quantitative extraction yield and chemical content of Mk LE
Sample

Extraction yields

Chemical composition

(%) = weight of sample Total phenols (mg
extract /sample
gallic acid equivalent
/g Mk LE)
weight) × 100
M.koenigii leaf
aqueous extract
(Mk LE)

15.63 ± 0.46

Values represented as means ± SD

46.78 ± 0.07

Total flavonoid (mg
catechin equivalent.
/g Mk LE)
6.1 ± 0.36

Chlorophyll
content (mg/
g Mk LE
0.40 ± 0.009

Alkaloid content
(mg bismuth
nitrate/g Mk LE)
37.9 ± 0.28

Total tannin (mg
tannic acid
equivalent /g Mk LE)
0.129 ± 0.008
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Fig. 2 Atheroma formation and resolution at the end of 26 weeks: (a) Control; with no atheromatous plaques formation (b) RHMVO fed group;
extensive atheromatous plaques formation, covered about 80–85% of the aortic arch (c) Mk LE-300 group; atheromatous plaque reduced to 60%
(d) Mk LE-500 group; atheromatous plaque reduced to 40% (e) lovastatin group; Atheromatous plaque reduced to 57%

from the statin group. Mk LE at a dose of 500 mg/kg
was found effective in a shorter period, to treat oxidative
damage and hyperlipidemia mediated by RHMVO compared to 300 mg/kg. The histopathological and macroscopic results showed that to treat RHMVO-induced
atherosclerosis the effect of MK LE in 500 mg/kg of

body weight is comparable with lovastatin, as all the
study parameters were significantly reduced in the Mk
LE-500 group.
Thermally oxidized oil is the most significant source
of oxidative damage for human health if used daily for a
long time. In RHMVO fed groups, highly elevated levels

Fig. 3 Histopathological finding of rabbits’ liver after 10 weeks of treatment. Control: a microscopic view of a normal liver. RHMVO fed group: a
microscopic view of fatty liver showing distended hepatocytes due to fat vacuoles. Mk LE-300 group: observed a lesser number of fat vacuoles
in the portal area. Mk LE-500 group: observed an insignificant number of fat vacuoles. Lovastatin group: observed an insignificant number of fat
vacuoles (200x magnification)
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of SGOT (extremely sensitive and a precise biomarker
for hepatotoxicity) and ALP (a main biomarker of hepatic and biliary defects like cholestasis) [72] reflected hepatocytes damage and tissue interruption, allowing the
leakage of intracellular enzymes in blood [73]. The liver
is damaged by excessive free radicals and may result in
hepatitis, cirrhosis, and hepatic tumor [74]. Consistent
with the diminished serum albumin and total protein
levels and supported by the significantly enlarged liver
and histopathological changes in hepatocytes of
RHMVO fed rabbits. The results of our study are consistent with the previous study, reported significantly reduced serum SGPT and SGOT levels in curry leaves
pretreated groups against the lead-induced model, a
clear indication of hepatic protection [75, 76], but the
maximum effective dose of curry leaves was 100 mg/kg
body weight.
The noticeable presence of carbazole alkaloids and
tannins in Mk LE analysis exhibit excellent hepatoprotective activity through their anti-lipid peroxidation and
antioxidant potential [77]. In the present study, Mk LE
considerably inhibited fat accumulation in hepatocytes
and the formation of hypercholesterolemia-induced atheroma. Besides, curry leaves extract attenuated lipid peroxidation and oxidative membrane injury in the organs
showing lipidosis. Statins are preferentially prescribed to
improve blood lipid profile through suppressing hepatic
cholesterol synthesis [11]. However, it’s reported in previous studies that long-term use and over-dosage of the
statins results in severe hepatotoxicity, whereas low
doses failed to control blood cholesterol levels effectively
from the diet [10–12]. Statins are reported to produce
adverse effects in up to 33% of patients [78]. Notably,
the management of cerebrovascular and cardiovascular
disease risk factors in preventive mode is more effective
than the therapeutic mode, as after the outbreak of these
diseases time to death is very short [11]. Therefore, it
has been recommended to follow dietary restrictions
and choose appropriate oils and fats. In addition, the excessive consumption of oils and fats especially in thermally oxidized form is also known to cause vascular
diseases, such as reduced vasorelaxation responses,
endothelial malfunction [16], lipid peroxidation [17],
atherosclerosis, and oxidative stress [19].
Reactive oxygen species (ROS) are free radicals with one
or more unpaired electrons. Major ROS include superoxide anion, hydrogen peroxide, and the hydroxyl radical
[79]. In addition to ROS, reactive nitrogen species (RNS),
including peroxynitrite (NO3-), nitric oxide radical (NO),
and S-nitrosothiols, also contribute to the generation of
oxidative stress. ROS are often generated as byproducts of
cellular metabolic reactions and exogenous induction.
These ROS produce homeostatic imbalances, and overwhelm cellular antioxidants defense system and results in
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oxidative stress, that further damage biomolecules such as
proteins, nucleic acids, and lipids which eventually, induces cell death and tissue injury [80, 81]. Subsequently
promotes the development of age-dependent diseases, like
cancer, atherosclerosis, arthritis, etc. [82]. MK LE has several potent antioxidants, such as isomahanine, isolongifolene, mahanine, mahanimbine, koenimbine,girinimbine,
koenoline, and O-methylmurrayamine [83, 84]. These antioxidants exhibit 2,2-diphenyl-1-picrylhydrazyl (DPPH)
free radical scavenging activity, inhibition of NO radical,
and thiobarbituric acid reactive substances (TBARS) activity [85, 86].
Mitochondria are the powerhouse of the living cell
and play a vital role in scavenging free radicals and controlling programmed cell death and/or the apoptosissignaling pathway [87]. RHMVO-induced mitochondrial
damage results in decreased adenosine triphosphate
(ATP) production, increased ROS generation, impaired
calcium buffering, damage to mitochondrial DNA
(mtDNA). An altered mitochondrial morphology and alterations in mitochondrial fission and fusion. Mitochondrial dysfunction is characterized by a loss of efficiency
in the electron transport chain, as well as reductions in
the synthesis of high-energy molecules [88]. Mitochondrial dysfunction is a characteristic of all chronic diseases including neurodegenerative disorders, CVDs,
diabetes, auto-immune diseases, atherosclerosis, and
others [89, 90].
Recent studies have evaluated the neuroprotective
activities of compounds isolated from MK LE. A
study reported that the bioactive compounds present
in MK LE exhibited the ability to repair the mitochondrial damage and restore the mitochondrial
membrane potential levels [91–93]. Previous findings
have demonstrated that MK LE and its primary active
compounds regulate multiple signaling pathways, including phosphatidylinositol 3 kinase (PI3K)/protein
kinase B (AKT), mammalian target of rapamycin
(mTOR) and mitogen-activated protein kinase
(MAPK). M. koenigii and its primary active compounds exert complementary effects on oxidative
stress and the alteration of proteins [94, 95].
The lipid-lowering activity of MK LE is reported in
several animal studies, in the different doses, in the
range of 80–600 mg [20, 21, 23]. To our knowledge, this
is the first animal study that evaluated the effect of MK
LE, in RHMVO-induced hypercholesterolemia in animals, also using the standard (lovastatin). In the dose of
500 mg/kg MK LE significantly reduced the TG, total
cholesterol, LDL, and VLDL, also, increased HDL levels
and reduced the cardiac infarction risk through the recovery of the arterial endothelial cells functions [96].
Better response with high doses is also supported by
other studies [20, 97]. The requirement of a longer
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duration to treat dyslipidemia is also supported by a previous study [97].
The high value of CRP is possibly indicative of developing cardiovascular disease, active inflammation, bacterial infection [98], and inflammatory bowel disease,
and other similar conditions like intestinal lymphoma
and tuberculosis [99]. Overexpression of CPK, homocysteine, and LDH has been linked with the number of
disorders including tissue damages, ROS induced inflammation, and endothelial cell injury [100]. The elevated
levels of all these tissues damaging markers are suggestive of increased risk of hypertension, diabetes, and CVDs
[101, 102]. Reduction in these parameters along with reduced oxidative stress is an additional benefit of MK LE,
compared to statins.
Moreover, it was demonstrated that MK LE inhibits
platelet aggregation when given with coriander extract
[23], thus further explains the MK LE potential to treat
RHMVO-induced
atherosclerosis.
Formation
of
thrombus and atherosclerosis takes place when vascular
endothelial walls get injured during oxidized LDLmediated oxidative reactions and activated platelets get
attached to this area. Therefore, curry leaves extract can
be the alternate option for investigators to treat hyperlipidemia, oxidative stress, and atherosclerosis medicated
by consumption of a higher amount of RHMVO in daily
life.

Conclusion
The results of this study conclude that Mk LE exhibits
potent antioxidant and antidyslipidemic properties that
can be used to treat RHMVO-induced hyperlipidemia
and atherosclerosis in optimal doses and duration. Over
the past few decades, the prevalence of coronary artery
diseases has increased significantly in South Asians and
predicted to be more than 24 million in 2035. Curry
leaves are basically of south Asian origin, so it can be
the better, easier, and cheaper option as nutrient supplement and remedy.
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